Cooper Companies (COO) Scheduled to Post Quarterly Earnings on Thursday

Cooper Companies (NYSE:COO – Get Rating) will be releasing its earnings data after the market closes on Thursday, June 1st. Analysts expect Cooper Companies to post earnings of $2.99 per share for the quarter. Cooper Companies has set its FY23 guidance at $12.60-12.90 EPS and its FY 2023 guidance at $12.60-$12.90 EPS.Parties that wish to register for the company’s conference call can do so using this link.

Cooper Companies (NYSE:COO – Get Rating) last announced its quarterly earnings results on Thursday, March 2nd. The medical device company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.66 by $0.24. The business had revenue of $858.50 million during the quarter, compared to analysts’ expectations of $834.90 million. Cooper Companies had a net margin of 11.10% and a return on equity of 8.39%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period last year, the business earned $3.24 earnings per share. On average, analysts expect Cooper Companies to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Cooper Companies Price Performance

COO stock opened at $377.97 on Thursday. The business’s 50-day moving average is $374.22 and its two-hundred day moving average is $345.62. The firm has a market capitalization of $18.69 billion, a P/E ratio of 50.06, a P/E/G ratio of 2.79 and a beta of 0.91. Cooper Companies has a 1 year low of $244.21 and a 1 year high of $395.20. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.72 and a quick ratio of 1.00.

Insider Buying and Selling

In related news, Director Robert S. Weiss sold 37,510 shares of the company’s stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $337.72, for a total transaction of $12,667,877.20. Following the completion of the sale, the director now directly owns 70,000 shares of the company’s stock, valued at approximately $23,640,400. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CAO Agostino Ricupati sold 1,000 shares of Cooper Companies stock in a transaction on Friday, March 31st. The shares were sold at an average price of $370.00, for a total value of $370,000.00. Following the completion of the sale, the chief accounting officer now owns 863 shares in the company, valued at $319,310. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert S. Weiss sold 37,510 shares of the business’s stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $337.72, for a total value of $12,667,877.20. Following the completion of the sale, the director now directly owns 70,000 shares of the company’s stock, valued at $23,640,400. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,726 shares of company stock valued at $13,451,962. 2.00% of the stock is currently owned by company insiders.

Institutional Trading of Cooper Companies

Several hedge funds have recently made changes to their positions in the stock. KB Financial Partners LLC acquired a new position in Cooper Companies during the 1st quarter valued at about $34,000. Clear Street Markets LLC boosted its stake in shares of Cooper Companies by 93.9% during the 1st quarter. Clear Street Markets LLC now owns 95 shares of the medical device company’s stock worth $35,000 after acquiring an additional 46 shares in the last quarter. Milestone Investment Advisors LLC purchased a new stake in shares of Cooper Companies during the first quarter valued at $86,000. Covestor Ltd increased its stake in Cooper Companies by 117.1% in the 1st quarter. Covestor Ltd now owns 280 shares of the medical device company’s stock worth $117,000 after purchasing an additional 151 shares in the last quarter. Finally, Loomis Sayles & Co. L P purchased a new stake in Cooper Companies during the first quarter valued at about $147,000. Institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on COO. Piper Sandler increased their price objective on Cooper Companies from $375.00 to $430.00 in a report on Wednesday. TheStreet raised shares of Cooper Companies from a “c+” rating to a “b-” rating in a research report on Friday, April 14th. Robert W. Baird raised their target price on shares of Cooper Companies from $371.00 to $385.00 in a research report on Friday, March 3rd. Citigroup upped their target price on shares of Cooper Companies from $372.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 3rd. Finally, StockNews.com started coverage on Cooper Companies in a report on Thursday, May 18th. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Cooper Companies currently has an average rating of “Moderate Buy” and a consensus price target of $398.80.

About Cooper Companies

(Get Rating)

The Cooper Cos, Inc operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues.